002424 多年财务造假！监管出手！

Group 1 - Guizhou Baikang (002424) has been penalized by the Guizhou Securities Regulatory Bureau for financial fraud, with the company and related parties receiving an administrative penalty notice [2] - The company reported false financial data in its annual reports for 2019, 2020, 2021, and 2023, leading to a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [2] - The company's stock will be suspended for one day starting December 22 and will resume trading on December 23 under the risk warning label "ST Baikang" [2] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and deterrence [3] - The bureau focuses on key individuals such as actual controllers, major shareholders, directors, and senior executives, as well as intermediary institutions [3] - Guizhou Baikang is a pharmaceutical company involved in the research, production, and sales of苗药 (苗药) and has several key products contributing to its profits [3]